Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients

International Journal for Equity in Health

Volumn 7, Issue , 2008, Pages

  Manderbacka, Kristiina ^a,c   Keskimäki, Ilmo ^a   Reunanen, Antti ^a   Klaukka, Timo ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b SOCIAL INSURANCE INSTITUTION   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; STATIN;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; MALE; SOCIOECONOMICS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 47349090546     PISSN: None     EISSN: 14759276     Source Type: Journal    
DOI: 10.1186/1475-9276-7-16     Document Type: Article

References (28)

1. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. MR Law NJ Wald AR Rudnicka, BMJ 2003 326 1423 1427 12829554 10.1136/bmj.326.7404.1423
2. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. R Collins R Peto S MacMahon, Lancet 1990 335 827 838 10.1016/0140-6736(90)90944-Z 1969567
3. Collaborative meta-analysis of randomised trials of antiplatent therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration, BMJ 2002 324 71 86 11786451 10.1136/bmj.324.7336.S71
4. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. D Wood G De Backer O Faergeman, Eur Heart J 1998 19 1434 1503 10.1053/euhj.1998.1243 9820987
5. Sepelvaltimotaudin ehkäisy käytännön lääkärintyössä. Yhteenveto eri yhdistysten yhteisen työryhmän (Second Joint Task Force of European and other societies) suosituksesta. D Wood G De Backer O Faergeman, (In Finnish with an English abstract: Prevention of coronary heart disease in clinical practice. A summary of recommendations of the Second Joint Task Force of European and other societies.) Suomen Lääkärilehti 1999 54 2107 2114
6. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. The EUROASPIRE I and II Group, Lancet 2001 357 995 1001 10.1016/S0140-6736(00)04235-5 11293642
7. Use of cardiovascular drugs by home-dwelling coronary patients aged 75 years and older. A population based cross-sectional survey in Helsinki, Finland. TE Strandberg K Pitkälä S Kulp RS Tilvis, Eur J Clin Pharmacol 2001 57 513 516 10.1007/s002280100311 11699618
8. Government resolution on the Health 2015 Public Health Programme. Ministry of Social Affairs and Health, Ministry of Social Affairs and Health Publications 2001
9. The meaning and goals of equity in health. W-C Chang, J Epidemiol Community Health 2002 56 488 491 12080154 10.1136/jech.56.7.488
10. Sex differences in risk factors, treatment and mortality after acute myocardial infarction: an observational study. B Hanratty DA Lawlor MB Robinson RJ Sapsford D Greenwood A Hall, J Epidemiol Community Health 2000 54 912 916 11076987 10.1136/jech.54.12.912
11. Use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarction. JZ Ayanian BE Landon MB Landrum JR Grana BJ McNeil, J Gen Intern Med 2002 17 95 102 11841524 10.1046/j.1525-1497.2002. 10438.x
12. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? FDA Reid DG Cook PH Whincup, Heart 2002 88 15 19 12067933 10.1136/heart.88.1.15
13. Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of health care need. PR Ward PR Noyce AS St Leger, Int J Equity Health 2005 4 3 15701165 10.1186/1475-9276-4-3
14. Trends in the treatment of patients with myocardial infarction and coronary revascularization procedures in Finland during 1986-92: the FINMONICA Myocardial Infarction Register Study. H Miettinen V Salomaa M Ketonen M Niemelä P Immonen-Räihä M Mähönen, J Intern Med 1999 245 11 20 10.1046/j.1365-2796.1999.00428.x 10095812
15. Relation of socioeconomic position to the case fatality, prognosis and treatment of myocardial infarction events; the FINMONICA MI Register Study. V Salomaa H Miettinen M Niemelä J Epidemiol Community Health 2001 55 475 482 11413176 10.1136/jech.55.7.475
16. Finnish Statistics on Medicines 2002. National Agency for Medicines and Social Insurance Institution, Helsinki 2003
17. Predictive margins with survey data. BI Graubard EL Korn, Biometrics 1999 55 652 659 10.1111/j.0006-341X.1999.00652.x 11318229
18. Aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed? AK McCallum PH Whincup RW Morris A Thomson M Walker S Ebrahim, Br J Gen Pract 1997 47 417 421 9281867
19. Diabetes and cardiovascular disease. HE Resnick BV Howard, Annu Med Rev 2002 53 245 267 10.1146/annurev.med.53.082901.103904
20. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. DA Alter CD Naylor P Austin P Austin JV Tu, N Engl J Med 1999 341 1359 1367 10.1056/NEJM199910283411806 10536129
21. Socioeconomic inequities in invasive cardiac procedures after first myocardial infarction in Finland in 1995. T Hetemaa I Keskimäki V Salomaa M Mähönen K Manderbacka S Koskinen, J Clin Epidemiol 2004 57 301 308 10.1016/j.jclinepi.2003.07.010 15066691
22. Coronary artery bypass graft surgery: socioeconomic inequalities in access and in 30 day mortality. A population based study in Rome, Italy. C Ancona N Agabiti F Forastiere, J Epidemiol Community Health 2000 54 930 935 11076990 10.1136/jech.54.12.930
23. How did the recent increase in the supply of coronary operations in Finland affect socio-economic and gender equity in their use? T Hetemaa I Keskimäki K Manderbacka AH Leyland S Koskinen, J Epidemiol Community Health 2003 57 178 185 12594194 10.1136/jech.57.3.178
24. Sepelvaltimotaudin riskitekijöiden sosioekonomiset erot. V Salomaa T Laatikainen H Tapanainen P Jousilahti E Vartiainen, (In Finnish with an English abstract: The role of socioeconomic differences in the prevalence and prevention of CHD). Suomen Lääkärilehti 2003 58 3187 3191
25. Health behaviour and health among Finnish adult population, Spring. S Helakorpi K Patja R Prättälä AR Aro A Uutela, Publications of the National Public Health Institute 2002 B12/2002:55-97
26. Low adherence with antihypertensive in actual practice: the association with social participation - a multilevel analysis. K Johnell L Råstam T Lithman J Sundquist J Merlo, BMC Public Health 2005 5 17 doi:10.1186/1471-2458- 5-17 15720716 10.1186/1471-2458-5-17
27. Effect of neighbourhood social participation on individual use of hormone replacement therapy and antihypertensive medication: a multilevel analysis. J Merlo JW Lynch M Yang M Lindström PO Östergren NK Rasmussen L Råstam, Am J Epidemiol 2003 157 774 78 10.1093/aje/kwg053 12727671
28. Self-administered questionnaire compared with a personal diary for assessment of current use of hormone therapy: an analysis of 16,060 women. J Merlo G Berglund E Wirfält B Gullberg B Hedblad J Manjer B Hovelius L Janzon BS Hanson PO Östergren, Am J Epidemiol 2000 152 788 792 10.1093/aje/152.8.788 11052558